MediciNova’s MN-001 for IPF Fails to Slow Lung Function Decline

MediciNova’s MN-001 for IPF Fails to Slow Lung Function Decline

303719

MediciNova’s MN-001 for IPF Fails to Slow Lung Function Decline

Six months of treatment with MN-001 (tipelukast), MediciNova’s investigational oral therapy, failed to significantly improve lung function in adults with idiopathic pulmonary fibrosis (IPF), according to data from a small Phase 2 clinical trial. The therapy, however, was associated with some positive effects, such as a reduction in worsening IPF events. Among the 10 participants with IPF given MN-001 at trial, there were no acute IPF exacerbations or hospitalizations due to respiratory symptoms, the data showed. “Although…

You must be logged in to read/download the full post.